ChengDu ShengNuo Biotec Co.,Ltd.

Equities

688117

CNE1000051M8

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-05-30 pm EDT 5-day change 1st Jan Change
25.13 CNY +1.82% Intraday chart for ChengDu ShengNuo Biotec Co.,Ltd. -1.45% -10.89%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sheng Nuo Biotec's Unit Gets Nod to Produce Posaconazole Injection MT
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Cheng Du Sheng Nuo Biotec Completes US FDA Filing For Constipation Drug API MT
Biocells Biotechnology Co., Ltd. announced that it has received funding from ChengDu ShengNuo Biotec Co.,Ltd., Xiamen Gaoxin Kechuang Angel Venture Capital Co., Ltd., Green Pine Capital Partners Co., Ltd. CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
ChengDu ShengNuo Biotec Co.,Ltd. cancelled the transaction announced on May 16, 2023 CI
Sheng Nuo Biotec's Unit Gets Nod to Amend Usage of Carbetocin Injection MT
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Three Cheng Du Sheng Nuo Biotec Execs to Divest Stakes MT
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
GermanLitho announced that it has received funding from Jingzhou Huaying Capital Venture Capital Management Partnership Enterprise (L.P.), ChengDu ShengNuo Biotec Co.,Ltd. CI
WNL Biomedtech announced that it has received funding from Huaying Capital, ChengDu ShengNuo Biotec Co.,Ltd. CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
ChengDu ShengNuo Biotec Co.,Ltd.(SHSE:688117) added to Shanghai Stock Exchange Composite Index CI
ChengDu ShengNuo Biotec Co.,Ltd.(SHSE:688117) added to Shanghai Stock Exchange A Share Index CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
ChengDu ShengNuo Biotec Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Meishan Huilong Pharmaceutical Technology Co., Ltd. announced that it expects to receive CNY 50 million in funding from ChengDu ShengNuo Biotec Co.,Ltd. CI
Chart ChengDu ShengNuo Biotec Co.,Ltd.
More charts
Cheng Du Sheng Nuo Biotec Co Ltd is a China-based company mainly engaged in the research and development of peptide active pharmaceutical ingredients (APIs) and preparation products. The Company's products target areas including immunology, digestive tract, antivirus, gynecology, diabetes, cardio-cerebrovascular, rare diseases, orthopedics and other fields. The Company is also engaged in customized peptide production services for customers, customized production services for peptide APIs and preparations, and technology transfer services for peptide drug production. The Company also provides small-molecule chemical drug Levosimendan preparations on behalf of processing, Levosimendan bulk drug production and export sales business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
25.13 CNY
Average target price
38 CNY
Spread / Average Target
+51.21%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688117 Stock
  4. News ChengDu ShengNuo Biotec Co.,Ltd.
  5. Cheng Du Sheng Nuo Biotec Completes US FDA Filing For Constipation Drug API